News | September 07, 2010

Clinical Trial Evaluates Peripheral Atherectomy Device in the Legs

September 7, 2010 – Enrollment started in the Endovascular Atherectomy Safety and Effectiveness (EASE) study to evaluate the safety and effectiveness of the Phoenix Atherectomy catheter. The minimally invasive device treats peripheral arterial disease (PAD) in the legs. The U.S. Food and Drug Administration (FDA)-approved investigational device exemption (IDE) clinical trial will enroll 90 patients at up to 20 clinical sites.

The first patient was treated by Craig Walker, M.D., an interventional cardiologist and medical director of the Cardiovascular Institute of the South in Houma, La. "The Phoenix Atherectomy device created a large, smooth channel in a totally occluded anterior tibial artery with no evidence of distal debris,” he said. “The device was easy to prep and quite easy to use. I am optimistic that this will be a useful tool in the treatment of atherosclerotic disease.”

The Phoenix is designed to cut, capture and convey arterial plaque into an external bag visible to the physician. The catheter is front-cutting and has a unique deflectable tip engineered to treat a range of blood vessel sizes with a single insertion of one, single-use device.

"We are excited to enroll the first patient in the EASE study to evaluate this promising new atherectomy technology," said Tom Davis, M.D., interventional cardiologist and director of peripheral interventions and disease at St. John’s Hospital in Detroit and the principal investigator for the EASE study. "I am enthusiastic about the potential for the Phoenix catheter to treat a wider range of arteries and disease with a single catheter. This technology could play a very impactful role in treating limb salvage patients and reducing leg amputations.”

The Phoenix Atherectomy catheter has CE mark in Europe.

For more information: www.atheromedinc.com

Related Content

PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...
New AHA Statement Highlights Need for Early Diagnosis, Treatment With Critical Limb IschemiaCTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer.

CTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer. PAD can lead to CLI.

News | Peripheral Artery Disease (PAD) | August 13, 2019
Non-invasive techniques and devices for assessing blood flow and other diagnostic considerations for people with ...
Endovascular-first Approach Equal to Open Surgery in Avoiding Amputation for Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | August 01, 2019
Less-invasive procedures to open severely clogged leg arteries were as good at helping people survive and avoid...
Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion
News | Peripheral Artery Disease (PAD) | July 17, 2019
A new analysis published by The Sage Group LLC concludes that the all-cause cost of critical limb ischemia (CLI)...
Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
Overlay Init